Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo.

Alkynes / pharmacology Animals Anti-Retroviral Agents / pharmacology HIV Infections / metabolism HIV-1 / drug effects Macaca mulatta Mice NF-kappa B / metabolism Oligopeptides / pharmacology Simian Acquired Immunodeficiency Syndrome / metabolism Simian Immunodeficiency Virus / drug effects Virus Latency / drug effects

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
02 2020
Historique:
received: 12 04 2019
accepted: 16 12 2019
pubmed: 24 1 2020
medline: 22 4 2020
entrez: 24 1 2020
Statut: ppublish

Résumé

Long-lasting, latently infected resting CD4

Identifiants

DOI: 10.1038/s41586-020-1951-3 PMID: 31969707 PMC: PMC7111210
pubmed: 31969707
doi: 10.1038/s41586-020-1951-3
pii: 10.1038/s41586-020-1951-3
pmc: PMC7111210
mid: NIHMS1546841
doi:

Substances chimiques

Alkynes 0
Anti-Retroviral Agents 0
N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide) 0
NF-kappa B 0
Oligopeptides 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

160-165

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH108179
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI126619
Pays : United States
Organisme : NIAID NIH HHS
ID : AI111899
Pays : United States
Organisme : NIAID NIH HHS
ID : AI123010
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI117851
Pays : United States
Organisme : NIAID NIH HHS
ID : AI1117851
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI096113
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123010
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW009532
Pays : United States
Organisme : NIH HHS
ID : S10 OD026799
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111899
Pays : United States
Organisme : NCI NIH HHS
ID : 5P30CA016086-41
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NIAID NIH HHS
ID : AI096113
Pays : United States
Organisme : NIMH NIH HHS
ID : MH108179
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI124436
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Finzi, D. et al. Latent infection of CD4
pubmed: 10229227
Archin, N. M. et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J. Clin. Invest. 127, 3126–3135 (2017).
pubmed: 28714868 pmcid: 5531421
Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
pubmed: 22837004 pmcid: 3704185
Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10, e1004473 (2014).
pubmed: 25393648 pmcid: 4231123
Gutiérrez, C. et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30, 1385–1392 (2016).
pubmed: 26891037
Kulkosky, J. et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186, 1403–1411 (2002).
pubmed: 12404155
Prins, J. M. et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13, 2405–2410 (1999).
pubmed: 10597782
Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21 (2014).
pubmed: 26423811
Søgaard, O. S. et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 11, e1005142 (2015).
pubmed: 26379282 pmcid: 4575032
Ke, R., Conway, J. M., Margolis, D. M. & Perelson, A. S. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. JCI Insight 3, e123052 (2018).
pmcid: 6237475
Sun, S. C. The noncanonical NF-κB pathway. Immunol. Rev. 246, 125–140 (2012).
pubmed: 22435551 pmcid: 3313452
Fulda, S. Molecular pathways: targeting death receptors and Smac mimetics. Clin. Cancer Res. 20, 3915–3920 (2014).
pubmed: 24824309
Pache, L. et al. BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe 18, 345–353 (2015).
pubmed: 26355217 pmcid: 4617541
Hennessy, E. J. et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J. Med. Chem. 56, 9897–9919 (2013).
pubmed: 24320998
Honeycutt, J. B. et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J. Clin. Invest. 128, 2862–2876 (2018).
pubmed: 29863499 pmcid: 6026008
Kessing, C. F. et al. In vivo suppression of HIV rebound by didehydro-cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Reports 21, 600–611 (2017).
pubmed: 29045830
Tsai, P. et al. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Retrovirology 13, 36 (2016).
pubmed: 27206407 pmcid: 4875645
Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12, 1316–1322 (2006).
pubmed: 17057712
Choudhary, S. K. et al. Latent HIV-1 infection of resting CD4
pubmed: 22013038 pmcid: 3255863
Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2012).
pubmed: 22013053 pmcid: 3255928
Wahl, A. et al. Precision mouse models with expanded tropism for human pathogens. Nat. Biotechnol. 37, 1163–1173 (2019).
pubmed: 31451733 pmcid: 6776695
Mavigner, M. et al. Simian immunodeficiency virus persistence in cellular and anatomic reservoirs in antiretroviral therapy-suppressed infant rhesus macaques. J. Virol. 92, e00562-18 (2018).
Mavigner, M. et al. Pharmacological modulation of the Wnt/β-catenin pathway inhibits proliferation and promotes differentiation of long-lived memory CD4 T cells in antiretroviral therapy-suppressed simian immunodeficiency virus-infected macaques. J. Virol. 94, e01094-19 (2019)
Abrahams, M. R. et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci. Transl. Med. 11, eaaw5589 (2019).
pubmed: 31597754 pmcid: 7233356
Anderson, E. M. & Maldarelli, F. The role of integration and clonal expansion in HIV infection: live long and prosper. Retrovirology 15, 71 (2018).
pubmed: 30352600 pmcid: 6199739
Ferris, A. L. et al. Clonal expansion of SIV-infected cells in macaques on antiretroviral therapy is similar to that of HIV-infected cells in humans. PLoS Pathog. 15, e1007869 (2019).
pubmed: 31291371 pmcid: 6619828
Kuo, H. H. & Lichterfeld, M. Recent progress in understanding HIV reservoirs. Curr. Opin. HIV AIDS 13, 137–142 (2018).
pubmed: 29232209 pmcid: 5806203
Clutton, G. T. & Jones, R. B. Diverse impacts of HIV latency-reversing agents on CD8
pubmed: 29988382 pmcid: 6023971
Gupta, R. K. et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 568, 244–248 (2019).
pubmed: 30836379 pmcid: 7275870
Hütter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009).
pubmed: 19213682
Nixon, C, C., Mavigner, M., Silvestri G. & Garcia, J. V. In vivo models of human immunodeficiency virus persistence and cure strategies. J. Infect. Dis. 215, S142–S151 (2017).
Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207–212 (2009).
pubmed: 19239360 pmcid: 2853863
Keedy, K. S. et al. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83, 4749–4756 (2009).
pubmed: 19279091 pmcid: 2682072
Trumble, I. M. et al. SLDAssay: a software package and web tool for analyzing limiting dilution assays. J. Immunol. Methods 450, 10–16 (2017).
pubmed: 28733216 pmcid: 5595663
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417–419 (2017).
pubmed: 28263959 pmcid: 5600148
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896
Denton, P. W. et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008).
pubmed: 18198941 pmcid: 2194746
Denton, P. W. et al. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 85, 7582–7593 (2011).
pubmed: 21593172 pmcid: 3147928
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
Palesch, D. et al. Short-term pegylated interferon α2a treatment does not significantly reduce the viral reservoir of simian immunodeficiency virus-infected, antiretroviral therapy-treated rhesus macaques. J. Virol. 92, e00279-18 (2018).
pubmed: 29720521 pmcid: 6026735
Hansen, S. G. et al. Addendum: immune clearance of highly pathogenic SIV infection. Nature 547, 123–124 (2017).
pubmed: 28636599
Li, H. et al. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl Acad. Sci. USA 113, E3413–E3422 (2016).
pubmed: 27247400 pmcid: 4914158
Krisko, J. F., Martinez-Torres, F., Foster, J. L. & Garcia, J. V. HIV restriction by APOBEC3 in humanized mice. PLoS Pathog. 9, e1003242 (2013).
pubmed: 23555255 pmcid: 3610649
Cartwright, E. K. et al. CD8
pubmed: 27653601 pmcid: 5087330
Rosenbloom, D. I. S., Hill, A. L., Laskey, S. B. & Siliciano, R. F. Re-evaluating evolution in the HIV reservoir. Nature 551, E6–E9 (2017).
pubmed: 29168805 pmcid: 6103791
Zimin, A. V. et al. A new rhesus macaque assembly and annotation for next-generation sequencing analyses. Biol. Direct 9, 20 (2014).
pubmed: 25319552 pmcid: 4214606
Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protocols 4, 44–57 (2009).
Li, J. et al. Isolation and transcriptome analyses of human erythroid progenitors: BFU-E and CFU-E. Blood 124, 3636–3645 (2014).
pubmed: 25339359 pmcid: 4256913
Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: Exploration and analysis of post cytometric complex multivariate datasets. Cytometry 79A, 167–174 (2014).

Auteurs

Christopher C Nixon (CC)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Maud Mavigner (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Gavin C Sampey (GC)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Qura Therapeutics, Chapel Hill, NC, USA.

Alyssa D Brooks (AD)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Rae Ann Spagnuolo (RA)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

David M Irlbeck (DM)

Qura Therapeutics, Chapel Hill, NC, USA.
HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA.

Cameron Mattingly (C)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Phong T Ho (PT)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Nils Schoof (N)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.

Corinne G Cammon (CG)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Greg K Tharp (GK)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.

Matthew Kanke (M)

Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Zhang Wang (Z)

GlaxoSmithKline Research and Development, Collegeville, PA, USA.

Rachel A Cleary (RA)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Amit A Upadhyay (AA)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.

Chandrav De (C)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Saintedym R Wills (SR)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Qura Therapeutics, Chapel Hill, NC, USA.

Shane D Falcinelli (SD)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Cristin Galardi (C)

Qura Therapeutics, Chapel Hill, NC, USA.
HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA.

Hasse Walum (H)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.

Nathaniel J Schramm (NJ)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Jennifer Deutsch (J)

GlaxoSmithKline Research and Development, Collegeville, PA, USA.

Jeffrey D Lifson (JD)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Christine M Fennessey (CM)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Brandon F Keele (BF)

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Sherrie Jean (S)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.

Sean Maguire (S)

GlaxoSmithKline Research and Development, Collegeville, PA, USA.

Baolin Liao (B)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.

Edward P Browne (EP)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Robert G Ferris (RG)

Qura Therapeutics, Chapel Hill, NC, USA.
HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA.

Jessica H Brehm (JH)

Qura Therapeutics, Chapel Hill, NC, USA.
HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA.

David Favre (D)

Qura Therapeutics, Chapel Hill, NC, USA.
GlaxoSmithKline Research and Development, Collegeville, PA, USA.

Thomas H Vanderford (TH)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.

Steven E Bosinger (SE)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Corbin D Jones (CD)

Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Jean-Pierre Routy (JP)

Chronic Viral Infection Service, McGill University Health Centre, Montreal, Quebec, Canada.
Division of Hematology, McGill University Health Centre, Montreal, Quebec, Canada.

Nancie M Archin (NM)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

David M Margolis (DM)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Qura Therapeutics, Chapel Hill, NC, USA.
Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Angela Wahl (A)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Richard M Dunham (RM)

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. richard.m.dunham@viivhealthcare.com.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. richard.m.dunham@viivhealthcare.com.
UNC HIV Cure Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. richard.m.dunham@viivhealthcare.com.
Qura Therapeutics, Chapel Hill, NC, USA. richard.m.dunham@viivhealthcare.com.
HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC, USA. richard.m.dunham@viivhealthcare.com.

Guido Silvestri (G)

Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Ann Chahroudi (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.
Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.
Emory + Children's Center for Childhood Infections and Vaccines, Atlanta, GA, USA. ann.m.chahroudi@emory.edu.

J Victor Garcia (JV)

International Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. victor_garcia@med.unc.edu.
Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. victor_garcia@med.unc.edu.
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. victor_garcia@med.unc.edu.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures acycliques › Alcynes › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Eucaryotes › Animaux › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Cercopithecidae › Cercopithecinae › Macaca › Macaca mulatta › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteur de transcription NF-kappa B › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Maladies de l'animal › Maladies des primates › Maladies des singes › Syndrome d'immunodéficience acquise du singe › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Rétrovirus simiens › Virus de l'immunodéficience simienne › Systemic HIV and SIV latency reversal via...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Latence virale › Systemic HIV and SIV latency reversal via...